Comparative Pharmacology
Head-to-head clinical analysis: TREPROSTINIL versus YUTREPIA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: TREPROSTINIL versus YUTREPIA.
TREPROSTINIL vs YUTREPIA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Treprostinil is a synthetic prostacyclin analogue that directly vasodilates pulmonary and systemic arterial beds, inhibits platelet aggregation, and suppresses vascular smooth muscle proliferation via activation of IP receptors and subsequent increase in cAMP levels.
YUTREPIA (treprostinil) is a prostacyclin analog that directly vasodilates pulmonary and systemic arterial beds and inhibits platelet aggregation. It binds to prostacyclin receptor (IP receptor), increasing cAMP in vascular smooth muscle cells, leading to vasodilation.
Continuous subcutaneous or intravenous infusion via infusion pump. Initial rate: 1.25 ng/kg/min; if not tolerated, reduce to 0.625 ng/kg/min. Titrate in increments of 1.25 ng/kg/min per week for first 4 weeks, then 2.5 ng/kg/min per week as tolerated. Typical maintenance dose: 25-40 ng/kg/min. Duration: continuous long-term.
0.6 mg/kg intravenously over 15 minutes every 3 weeks until disease progression or unacceptable toxicity.
None Documented
None Documented
Clinical Note
moderateTreprostinil + Benzydamine
"The risk or severity of adverse effects can be increased when Treprostinil is combined with Benzydamine."
Clinical Note
moderateTreprostinil + Droxicam
"The risk or severity of adverse effects can be increased when Treprostinil is combined with Droxicam."
Clinical Note
moderateTreprostinil + Loxoprofen
"The risk or severity of adverse effects can be increased when Treprostinil is combined with Loxoprofen."
Clinical Note
moderateTreprostinil + Clonixin
Terminal half-life is approximately 4 hours for intravenous administration; clinical context: requires continuous infusion due to short half-life.
Terminal elimination half-life: 12-15 hours (range 11-18 h) in adults; prolonged in renal impairment (CrCl <30 mL/min: up to 30 h).
Primarily hepatic metabolism via CYP2C8; renal excretion of unchanged drug is approximately 4% of the dose.
Renal: 80% as unchanged drug; fecal: 15% as metabolites; biliary: <5%.
Category A/B
Category C
Prostacyclin Analog
Prostacyclin Analog
"The risk or severity of adverse effects can be increased when Treprostinil is combined with Clonixin."